Hematologic Oncology | Specialty

Expert Discusses Strategies for Advancing Pediatric ALL Care

September 20th 2017

The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.

EU Approves Midostaurin for AML, Advanced Systemic Mastocytosis

September 20th 2017

The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia and advanced systemic mastocytosis.

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy

September 20th 2017

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL

September 19th 2017

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

Ibrutinib Highly Active Against MCL in Pooled Analysis

September 19th 2017

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

Venetoclax Combination Improves PFS in Phase III CLL Trial

September 19th 2017

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Lower Dose ATLG Safer, More Effective in Children With Hematologic Malignancies

September 15th 2017

A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

FDA Approves Copanlisib for Follicular Lymphoma

September 14th 2017

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

Early Administration of Cytarabine May Improve Survival in Pediatric ML-DS

September 13th 2017

Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome during the second chemotherapy induction cycle resulted in improved event-free survival and overall survival compared to results observed in previous research studies.

FDA Accepts Application for Rituximab Biosimilar

September 12th 2017

The FDA has accepted a biologics license application for the rituximab biosimilar Rixathon, according to Sandoz, the company developing the treatment.

FDA Places Holds on Several Durvalumab Combination Trials

September 8th 2017

The FDA has placed clinical holds on multiple trials in Celgene’s FUSION program, which is exploring regimens combining the PD-L1 inhibitor durvalumab with immunomodulatory and chemotherapy agents across several hematologic malignancies.

FDA Approves Gemtuzumab Ozogamicin for Newly Diagnosed CD33+ AML

September 1st 2017

The FDA has approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia.

Novel Agent HXR9 Attacks New Target in AML

August 31st 2017

Richard Morgan, MD, discusses recent research involving therapy with HXR9 for patients with AML.

Novartis Sets a Price of $475,000 for CAR T-Cell Therapy

August 31st 2017

Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy

August 30th 2017

The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.

FDA Grants Frontline Bosutinib Priority Review in CML

August 30th 2017

The FDA has granted a priority review to a supplemental new drug application for bosutinib for the first-line treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017